BASKING RIDGE, N.J., Jan. 20, 2009 (GLOBE NEWSWIRE) -- Millennium Biotechnologies Group, Inc. (OTCBB:MBTG) a leader in the development of targeted nutritional products in the Clinical Nutrition Market and Sports Nutrition Market, announced today that its clinical recovery and performance trial in Division 1 Athletes will be published in The Journal of Strength and Conditioning Research ("JSCR").
JSCR is the official research journal of the National Strength and Conditioning Association, ("NSCA"). This journal is recognized as the preeminent publication for strength and conditioning coaches worldwide. These thought leaders rely on this journal for the future of leading edge science as applied to their profession.
"There is a vast difference between Surgex(r) and the status quo branded products on the marketplace that do not address the multiple nutritional needs of the athlete," states Carl Germano, RD, CNS, CDN, Sr. VP Research & Product Development for MBI. "The publication of this study unquestionably leverages the value of our long standing and well accepted clinical products and our patent-protected science and its success has now been translated into our ground breaking sports product line."
Mark C. Mirken, CEO and Chairman of the Board stated, "The value of this study and the publication of its results in this well received and widely accepted journal will accelerate the launch the successful commercialization of our Surgex sports product line. It will facilitate and accelerate our ongoing dialogues, which we are deeply engaged in with a number of global partners to develop and distribute Surgex. We are firmly convinced that our recognition by this publication will greatly enhance our company's ability, in the near term, to significantly increase shareholder value."
About Millennium
Millennium's six marketed products form an advanced line of nutritional formulas. Resurgex Select(r) is a whole foods-based, calorically dense, high-protein nutritional formula developed for cancer patients undergoing chemotherapy or radiation treatments. Resurgex(r) and Resurgex Plus(r) are specialized, anabolic nutritional supplements rich in antioxidants that provide nutritional support post-treatment. Millennium also created Surgex(tm) sports nutrition formula to address the nutritional concerns of professional, Olympic, and amateur elite athletes. These athletes often experience similar symptoms post-workout to those battling immuno-compromised conditions, such as fatigue, loss of lean muscle, oxidative stress, and reduced immune function. Resurgex Essential(tm) and Resurgex Essential Plus(tm) are comprehensive, calorically dense formulas that meet and exceed the nutritional requirements of the assisted living community.
Statements in this news release regarding future financial and operating results, future growth in R&D programs, potential applications of the Millennium's technology, opportunities for the Millennium, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words 'will,' 'believes,' 'plans,' 'anticipates,' 'expects,' 'estimates,' and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward- looking statements including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of Millennium's intellectual property, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in Millennium's periodic reports, including Forms 10-KSB, 10-QSB, 8-K, and other forms filed with the Securities and Exchange Commission ('SEC').